Tag: trial
Optimal RRT for Critically Ill Patients with Severe AKI
In critically ill patients with severe acute kidney injury (AKI), initiation of continuous renal replacement therapy (CRRT), as compared to intermittent hemodialysis (IHD), was associated with a significant reduction in the... read more
Haloperidol and Delirium: What is Next?
Haloperidol is, by far, the best-studied antipsychotic in ICU, appears to be safe in the dosing range used in these two trials and is easy to administer and titrate. For these reasons, if a clinician chooses to pharmacologically... read more
Delirium in Critically Ill Patients – Haloperidol Treatment
Haloperidol may reduce mortality and likely result in little to no change in the occurrence of SAEs/SARs compared with placebo in critically ill patients with delirium. However, the results were not statistically significant... read more
AKI Defined by Fluid-Corrected Creatinine in Premature Neonates
In this secondary analysis of the multicenter PENUT trial, we describe fluid-corrected acute kidney injury (AKI) and evaluate associations with short-term and long-term outcomes in premature neonates with fluid-corrected... read more
Ciprofol Sedation Efficacy and Safety in Mechanical Ventilated ICU Patients
Ciprofol was well tolerated, with a noninferior sedation profile to propofol in Chinese ICU patients undergoing MV for a period of 6–24 hours. Of the 135 patients enrolled, 129 completed the study. The primary endpoint-sedation... read more
Duration of Device-Based Fever Prevention After Cardiac Arrest
While fever prevention for 72 hours after cardiac arrest has been endorsed by international guidelines since 2005, there is a lack of randomized control trial (RCT) generated data supporting this after the initial 24 hours... read more
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding... read more
Are Two Shocks Better Than One?
Overall, the trial conducted by Cheskes et al contributes meaningfully to our understanding of the use of alternative defibrillation strategies for refractory ventricular fibrillation before widespread incorporation of double... read more
Hydrocortisone in Severe Community-Acquired Pneumonia
Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. A total of 800 patients had undergone... read more
No Benefits For Using 4-Factor Prothrombin Complex Concentrate (4F-PCC) in Trauma Patients
Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed. Among over 300 patients... read more
Oral PCSK9 Inhibitor Could Help Reduce LDL-C by 60%
New research from a phase 2b trial presented at American College of Cardiology meeting (ACC) 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular... read more
Postoperative Pulmonary Complications in the ENIGMA II Trial
Respiratory complications remain among the most common and serious adverse outcomes of major surgery. In the Australian and New Zealand Audit of Surgical Mortality, postoperative pneumonia accounted for 44% of infective... read more
The CLOVERS Trial: Does Nothing Matter in Sepsis?
The CLOVERS trials is an open label RCT that did not demonstrate any difference (beneficial or harmful) from using a restrictive fluid strategy over a liberal fluid strategy in sepsis-induced hypotension. Do whatever... read more
Delirium Prevention in the ICU: Melatonin or Ramelteon
Melatonin modulates the circadian rhythm and has been studied as a preventive measure against the development of delirium in hospitalized patients. Such an effect may be more evident in patients admitted to the ICU, but findings... read more
Baricitinib or Tocilizumab for Severe COVID-19 Treatment
Pharmacologic treatment of COVID-19 has continued to evolve since the onset of the pandemic, and yet many questions remain about optimal treatment. Medicine strives to provide evidence-based guidance on treatments, but... read more
Remote Ischemic Conditioning in Septic Shock
The treatment known as RECO did not significantly reduce the severity of organ failure as measured by the mean daily SOFA (sequential organ failure assessment) score from the start of the study to day 4 in patients with septic... read more
Molnupiravir Improves Recovery Time in COVID-19 Patients at High Risk of Severe Outcomes
This analysis of a large randomized trial involving people who are at high risk of experiencing severe outcomes from COVID-19 and who had been vaccinated against SARS-CoV-2 infection found that adding molnupiravir to usual... read more
